- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
- Premium Tools
- Real Money
- Real Money Pro
- Action Alerts PLUS
- Stocks Under $10
- Breakout Stocks
- Options Profits
Latest Commentary
Real Money: Independent market insight from a veteran team of trusted Wall Street pros.
• Up-to-the-minute reports on market activity
• Actionable trade ideas
• Up-to-the-minute reports on market activity
• Actionable trade ideas
Latest Strategies
Real Money Pro: Professional tools and specific trade ideas for active investors.
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
Latest Alert
May 24, 2013 | 06:41 PM EDT
We remain overweight in industrials, materials, energy and financials. FULL ALERT »
Action Alerts PLUS: Jim Cramer and Stephanie Link actively manage a real money portfolio for Jim's charitable trust.
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
Latest Alert
May 24, 2013 | 04:28 PM EDT
As stocks ended their four-week winning streak this week, we used the volatility to trim one model portfolio position. FULL ALERT »
Stocks Under $10: David Peltier manages a portfolio of affordable stocks with huge upside potential.
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
Latest Alert
May 24, 2013 | 08:41 AM EDT
This name issued a near-perfect fiscal third-quarter earnings report and bumped its full-year guidance higher. FULL ALERT »
Breakout Stocks: Bryan Ashenberg, CFA, manages a portfolio of small and mid-cap stocks with high growth potential.
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
Latest Commentary
Options Profits: Day in and day out, our team of professional options traders search for inventive plays for trading spikes in market activity, emerging trends, and breaking news and events. These veterans reveal all their charts and technical data — delivering daily strategies and insightful commentary written specifically for the options trader plus 40 options trade ideas per week!
Questcor Pharmaceuticals Inc. (QCOR)
QCOR (NASDAQ:Drugs)
$34.86
-0.43
-1.22%
Today's Range: 34.02 - 35.42 |
QCOR Avg Daily Volume: 1,988,700
| Last Update: 05/24/13 - 4:00 PM EDT |
| Volume: 1,373,635 |
| YTD Performance: 32.07% |
| Open: $35.33 |
| Previous Close: $35.29 |
| 52 Week Range: $17.25 - $58.91 |
| Oustanding Shares: 59,554,145 |
| Market Cap: 2,101,665,777 |
Analysts Ratings
| Historical Rec | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago |
|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 2 | 1 | 1 | 2 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.57 | 1.29 | 1.29 | 1.50 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $1.13 | $1.12 | $4.06 | $4.01 |
| Number of Analysts | 1 | 1 | 1 | 1 |
| High Estimate | $1.13 | $1.12 | $4.06 | $4.01 |
| Low Estimate | $1.13 | $1.12 | $4.06 | $4.01 |
| Prior Year | $0.65 | $0.92 | $3.15 | $4.06 |
| Growth Rate (Year over Year) | 73.85% | 21.74% | 28.89% | -1.23% |
TradingTrooper: updated: weekly options w/short interest >15% http://t.co/KsxU6VVzfs $QCOR $UNXL $TSLA $VHC $DNDN $HLF $GME $IOC $MCP http://t.co/UtdEr6plRl
12 hours ago from TweetDeck
12 hours ago from TweetDeck
bkparx: George Soros bought more $SRPT. Holds over 400K shares http://t.co/4wTef6shth $SPY $QCOR $QQQ $JAZZ
1 day ago from Twitter for iPhone
1 day ago from Twitter for iPhone
julztrades: RT @YoungMarketMavn: $P 18.75 first key level, then $20 magnet. about 34 million shares short, short squeezes are hot topic this is next. $TSLA $GMCR $FSLR $QCOR
1 day ago from Twitter for BlackBerry
1 day ago from Twitter for BlackBerry
bluser12: RT @YoungMarketMavn: $P 18.75 first key level, then $20 magnet. about 34 million shares short, short squeezes are hot topic this is next. $TSLA $GMCR $FSLR $QCOR
2 days ago from Plume for Android
2 days ago from Plume for Android
YoungMarketMavn: $P 18.75 first key level, then $20 magnet. about 34 million shares short, short squeezes are hot topic this is next. $TSLA $GMCR $FSLR $QCOR
2 days ago from web
2 days ago from web
Questcor Pharmaceuticals numbers raised at Jefferies
Shares of QCOR now seen reaching $38, Jefferies said. Estimates also raised on Strong 4Q with robust 2013 outlook. Buy rating.
Martin Zweig had a colorful style and an insightful approach.
Questcor upgraded at Mizuho
QCOR was upgraded from Neutral to Buy, Mizuho said. $41 price target. Company should exceed consensus expectations in the near term.
Questcor Pharmaceuticals upgraded at Jefferies
Shares of QCOR upgraded to Buy from Hold, Jefferies said. $28 price target. Limited downside with improved visibility.
Questcor downgraded at Leerink
QCOR was downgraded to Market Perform, Leerink Swann said. Valuation call, following Aetna's Acthar decision.
Disappointing earnings results have sent this name cascading lower.
Questcor Pharmaceuticals numbers lowered at Oppenheimer
Shares of QCOR now seen reaching $65, Oppenheimer said. Estimates also lowered on revision of Acthar coverage. Outperform rating.
Questcor Pharmaceuticals downgraded at Jefferies
Shares of QCOR downgraded to Hold from Buy, Jefferies said. $30 price target. Aetna policy change is explicit.
Questcor estimates, target cut at BofA/Merrill
Shares of QCOR now seen reaching $45, according to Bank of America/Merrill Lynch. Estimates also reduced, following AET changes for Acthar. Buy rating.
The worst case is priced in, and any positive news would send this one soaring.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
© 2013 TheStreet, Inc. All rights reserved.